Pfizer (PFE) Current Deferred Tax Assets (2010 - 2026)
Pfizer (PFE) posted quarterly Current Deferred Tax Assets of $3.6 billion for Q1 2026, up 23.72% year-over-year from $2.9 billion in Q1 2025, and down 9.55% quarter-over-quarter from $4.0 billion in Q4 2025.
Pfizer (PFE) Current Deferred Tax Assets (2010 - 2026) Analysis & Trends
Pfizer (PFE) has reported Current Deferred Tax Assets for 17 consecutive years, with $3.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Tax Assets rose 23.72% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 23.72% YoY), while the FY2025 annual figure was $4.0 billion, up 19.7% from the prior year.
- Current Deferred Tax Assets retreated to $3.6 billion in Q1 2026 per PFE's latest filing, from $4.0 billion in the prior quarter.
- Across five years, Current Deferred Tax Assets topped out at $4.2 billion in Q1 2024 and bottomed at $2.6 billion in Q3 2022.
- Historically, Current Deferred Tax Assets has averaged $3.5 billion across 5 years, with a median of $3.6 billion in 2022.
- Annual changes were most pronounced in 2024 — Current Deferred Tax Assets jumped 34.81% — and 2025, when it slumped 31.49%.
- Pfizer's Current Deferred Tax Assets stood at $3.6 billion in 2022, then increased by 11.21% to $4.0 billion in 2023, then fell by 16.69% to $3.3 billion in 2024, then climbed by 19.7% to $4.0 billion in 2025, then declined by 9.55% to $3.6 billion in 2026.
- Business Quant data shows PFE's Current Deferred Tax Assets at $3.6 billion in Q1 2026, $4.0 billion in Q4 2025, and $3.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 3.70 Bn |
| Jun 28, 2026 | 3.70 Bn |
| Mar 29, 2026 | 3.59 Bn |
| Mar 29, 2026 | 3.59 Bn |
| Dec 31, 2025 | 3.97 Bn |
| Dec 31, 2025 | 3.97 Bn |
| Sep 28, 2025 | 3.86 Bn |
| Sep 28, 2025 | 3.86 Bn |
| Jun 29, 2025 | 4.02 Bn |
| Jun 29, 2025 | 4.02 Bn |
| Mar 30, 2025 | 2.90 Bn |
| Mar 30, 2025 | 2.90 Bn |
| Dec 31, 2024 | 3.31 Bn |
| Dec 31, 2024 | 3.31 Bn |
| Sep 29, 2024 | 3.24 Bn |
| Sep 29, 2024 | 3.24 Bn |
| Jun 30, 2024 | 3.69 Bn |
| Jun 30, 2024 | 3.69 Bn |
| Mar 31, 2024 | 4.23 Bn |
| Mar 31, 2024 | 4.23 Bn |